LoriAnnPantherMDMPH

Vice President, Clinical Development, Infectious Diseases, Moderna, Inc.

Dr. Panther is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

University of WashingtonFellowship, Infectious Disease, 1990 - 1993
University of California (San Francisco)Residency, Internal Medicine, 1986 - 1990
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1986

PubMed

Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
Kai Wu, Yixuan Jacob Hou, Dan Makrinos, Runxia Liu, Alex Zhu, Matthew Koch, Wen-Han Yu, Yamuna D Paila, Sumana Chandramouli, Carole Henry, Anthony DiPiazza, Andrea Car...> ;Journal of Virology. 2024 Apr 16
8 citations
Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults.
Allison August, Christine A Shaw, Heather Lee, Conor Knightly, Shiva Kalidindia, Laurence Chu, Brandon J Essink, William Seger, Tal Zaks, Igor Smolenov, Lori Panther> ;Open Forum Infectious Diseases. 2022 Jul 1
18 citations
Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.
Lori A Panther, Hans P. Schlecht, Bruce J. Dezube> ;The AIDS Reader. 2005 Feb 1

Investigational Vaccine Targeting CMV, the #1 Infectious Cause of Birth Defects in the U.S.June 3rd, 2022
Pursuing Victory: Moderna Begins Dosing in Phase III CMV TrialNovember 8th, 2021